Atezolizumab (MPDL3280A) monotherapy for patients with metastatic urothelial cancer long-term outcomes from a phase 1 study

JAMA Oncology

Volumn 4, Issue 4, 2018, Pages 537-544

  Petrylak, Daniel P ^a   Powles, Thomas ^b   Bellmunt, Joaquim ^c   Braiteh, Fadi ^d,e   Loriot, Yohann ^f   Morales Barrera, Rafael ^g   Burris, Howard A ^h   Kim, Joseph W ^a   Ding, Beiying ⁱ   Kaiser, Constanze ⁱ   Fasso, Marcella ⁱ   O’Hear, Carol ⁱ   Vogelzang, Nicholas J ^d,e  

^a YALE CANCER CENTER   (United States)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

^e Division of Hematology and Medical Oncology   (United States)

^f INSTITUT GUSTAVE ROUSSY   (France)

^g HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^h SARAH CANNON RESEARCH INSTITUTE   (United States)

ⁱ GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATEZOLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; MONOCLONAL ANTIBODY;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; CANCER TISSUE; CHILL; CLINICAL OUTCOME; COHORT ANALYSIS; COUGHING; DECREASED APPETITE; DISEASE SEVERITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; DYSGEUSIA; EASTERN COOPERATIVE ONCOLOGY GROUP PERFORMANCE STATUS; EUROPE; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; HYPERTHYROIDISM; IMMUNOCOMPETENT CELL; LETHARGY; LYMPHOCYTOPENIA; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; METASTASIS; METASTATIC UROTHELIAL CARCINOMA; MIDDLE AGED; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PRURITUS; RASH; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; SIDE EFFECT; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; TUMOR ASSOCIATED LEUKOCYTE; VERY ELDERLY; ADVERSE DRUG REACTION; BLADDER TUMOR; CLINICAL TRIAL; DOSE RESPONSE; MORTALITY; PATHOLOGY; SURVIVAL ANALYSIS; TIME FACTOR; UROTHELIUM;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; CARCINOMA, TRANSITIONAL CELL; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; SURVIVAL ANALYSIS; TIME FACTORS; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 85047475503     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2017.5440     Document Type: Article

References (26)

1. Bellmunt J, Orsola A, Leow JJ, Wiegel T, De Santis M, Horwich A; ESMO Guidelines Working Group. Bladder cancer: ESMO practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(suppl 3):iii40-iii48.
2. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer. V5.2017. https://www.nccn.org /professionals/physician_gls/pdf/bladder.pdf. Accessed September 7, 2017.
3. Tecentriq (atezolizumab) [package insert]. South San Francisco, CA: Genentech, Inc; 2017.
4. Opdivo (nivolumab) [package insert]. New York, NY: Bristol-Myers Squibb; 2017.
5. Keytruda (pembrolizumab) [package insert]. Whitehouse Station, NJ; 2017.
6. Imfinzi (durvalumab) [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2017.
7. Bavencio (avelumab) [package insert]. New York, NY: EMD Serono, Inc, and Pfizer Inc; 2017.
8. Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563-567.
9. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1-10.
10. McDermott DF, Sosman JA, Sznol M, et al. Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia study. J Clin Oncol. 2016; 34(8):833-842.
11. Rittmeyer A, Barlesi F, Waterkamp D, et al; OAK Study Group. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255-265.
12. Powles T, Eder JP, Fine GD, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014;515(7528): 558-562.
13. Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031): 1909-1920.
14. Balar AV, Galsky MD, Rosenberg JE, et al; IMvigor210 Study Group. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017;389(10064):67-76.
15. Tecentriq (atezolizumab) [package insert]. Welwyn Garden City, United Kingdom: Roche Registration Ltd; 2017.
16. Fehrenbacher L, Spira A, Ballinger M, et al; POPLAR Study Group. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;387(10030):1837-1846.
17. Bellmunt J, de Wit R, Vaughn DJ, et al; KEYNOTE-045 Investigators. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015-1026.
18. Surveillance, Epidemiology, and End Results Program. Cancer stat facts: bladder cancer. https://seer.cancer.gov/statfacts/html/urinb.html. Accessed April 28, 2017.
19. Bellmunt J, Théodore C, Demkov T, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol. 2009;27(27):4454-4461.
20. Massard C, Gordon MS, Sharma S, et al. Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol. 2016;34(26): 3119-3125.
21. Sharma P, Callahan MK, Bono P, et al. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet Oncol. 2016;17(11):1590-1598.
22. Apolo AB, Infante JR, Balmanoukian A, et al. Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase Ib study. J Clin Oncol. 2017;35(19):2117-2124.
23. Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017;18 (3):312-322.
24. Plimack ER, Bellmunt J, Gupta S, et al. Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. Lancet Oncol. 2017;18(2):212-220.
25. Perez-Gracia JL, Loriot Y, Rosenberg JE, et al. Atezolizumab (atezo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): outcomes by prior therapy. 2017;35(suppl 6S):abstr 323.
26. Powles T, Loriot Y, Durán I, et al. IMvigor211: a phase III randomized study examining atezolizumab versus chemotherapy for platinum-treated advanced urothelial carcinoma. Paper presented at: European Association for Cancer Research–American Association for Cancer Research–Italian Cancer Society Special Conference 2017; June 24–27, 2017; Florence, Italy.